Insider · CIK 0001290208
Michael B Hoffman
Files at ANVS (Annovis Bio, Inc.), TDAC (Translational Development Acquisition Corp.). First filing Nov 12, 2025, latest May 21, 2026.
In brief
Michael B Hoffman files SEC Form 4 as director, CEO, chair and 10% owner at ANVS (Annovis Bio, Inc.), and also at TDAC (Translational Development Acquisition Corp.). Since Nov 12, 2025, Michael B Hoffman has reported 8 open-market buys worth $4.3M and 0 open-market sells worth $0, the latest filed on May 21, 2026.
A track record needs three past buys with six months of prices behind them; Michael B Hoffman has 0, so none is measured yet.
The newest scored trade: bought $143k of ANVS on May 20, 2026, filed May 21, 2026, scored 39 (weak). In the last 12 months: 8 buys worth $4.3M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ANVS: Annovis Bio, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | ANVSbuy Annovis Bio, Inc. | $143k 76,344 shares | +2% | +28% from low-60% from high | |
| 54Moderate | ANVSbuy Annovis Bio, Inc. | $1.5M 713,800 shares | +28% | +87% from low-55% from high | |
| 32Weak | ANVSbuy Annovis Bio, Inc. | $194k 45,000 shares | +2% | - | |
| 31Weak | ANVSbuy Annovis Bio, Inc. | $160k 39,200 shares | +2% | - | |
| 31Weak | ANVSbuy Annovis Bio, Inc. | $160k 39,200 shares | +2% | - | |
| 23Weak | ANVSbuy Annovis Bio, Inc. | $70k 20,000 shares | +1% | - | |
| 20Weak | ANVSbuy Annovis Bio, Inc. | $32k 15,000 shares | +1% | - | |
| 58Moderate | Annovis Bio, Inc. | $2.0M 975,610 shares | +66% | - |
Transactions
Every row this insider has filed, 30 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 27, 2026 | TDAC Translational Development Acquisition Corp. | POpen-market purchase Warrantsderivative | +53,395 | $0.79 | $42k | 53,395 | May 29, 2026 |
| May 20, 2026 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +2,562 | $1.75 | $4,484 | 3,291,101 | May 21, 2026 |
| May 20, 2026 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +18,849 | $1.80 | $34k | 3,309,950 | May 21, 2026 |
| May 20, 2026 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +54,933 | $1.90 | $104k | 3,364,883 | May 21, 2026 |
| Apr 2, 2026 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +713,800 | $2.10 | $1.5M | 3,288,539 | Apr 3, 2026 |
| Dec 8, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +30,000 | $4.34 | $130k | 2,559,739 | Dec 8, 2025 |
| Dec 8, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +15,000 | $4.24 | $64k | 2,574,739 | Dec 8, 2025 |
| Nov 24, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +1,489 | $4.13 | $6,150 | 2,482,028 | Nov 25, 2025 |
| Nov 24, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +1,489 | $4.13 | $6,150 | 2,492,028 | Nov 25, 2025 |
| Nov 24, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +9,200 | $3.85 | $35k | 2,491,228 | Nov 25, 2025 |
| Nov 24, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +9,200 | $3.85 | $35k | 2,501,228 | Nov 25, 2025 |
| Nov 24, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +415 | $4.14 | $1,718 | 2,491,643 | Nov 25, 2025 |
| Nov 24, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +415 | $4.14 | $1,718 | 2,501,643 | Nov 25, 2025 |
| Nov 24, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +28,096 | $4.15 | $117k | 2,519,739 | Nov 25, 2025 |
| Nov 24, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +28,096 | $4.15 | $117k | 2,529,739 | Nov 25, 2025 |
| Nov 21, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +10,000 | $3.49 | $35k | 2,480,539 | Nov 21, 2025 |
| Nov 21, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +10,000 | $3.50 | $35k | 2,490,539 | Nov 21, 2025 |
| Nov 14, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +15,000 | $2.11 | $32k | 2,470,539 | Nov 18, 2025 |
| Oct 28, 2025 | ANVS Annovis Bio, Inc. | POpen-market purchase Common Stock | +975,610 | $2.05 | $2.0M | 2,455,539 | Nov 12, 2025 |
| Aug 29, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +5,000 | $2.28 | $11k | 1,469,929 | Sep 3, 2025 |
| Aug 29, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +5,000 | $2.29 | $11k | 1,474,929 | Sep 3, 2025 |
| Aug 29, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +5,000 | $2.30 | $12k | 1,479,929 | Sep 3, 2025 |
| Aug 19, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +6,717 | $2.60 | $17k | 1,453,001 | Aug 20, 2025 |
| Aug 19, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +5,283 | $2.59 | $14k | 1,458,284 | Aug 20, 2025 |
| Aug 19, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +5,545 | $2.58 | $14k | 1,463,829 | Aug 20, 2025 |
| Aug 19, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +1,100 | $2.57 | $2,827 | 1,464,929 | Aug 20, 2025 |
| Jun 13, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +25,000 | $2.80 | $70k | 1,446,283 | Jun 16, 2025 |
| Jun 13, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +1 | $2.83 | $3 | 1,446,284 | Jun 16, 2025 |
| May 29, 2025 | ANVS Annovis Bio, Inc. | AGrant or award Common Stock | +5,000 | $2.43 | $12k | 1,421,283 | Jun 2, 2025 |
| Nov 20, 2023 | ANVS Annovis Bio, Inc. | AGrant or award Common Stockindirect: The 2018 Jane and Michael Hoffman Descendants Trust | +164,745 | $6.07 | $1.0M | 224,222 | Nov 21, 2023 |
Questions about Michael B Hoffman
Answered from the filings on this page, as of the latest one.
Is Michael B Hoffman buying or selling?
In the last 12 months Michael B Hoffman reported 8 open-market buys worth $4.3M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $143k of ANVS on May 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Michael B Hoffman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Michael B Hoffman has 0.
Where does Michael B Hoffman file Form 4?
Michael B Hoffman has filed Form 4 at ANVS (Annovis Bio, Inc.); TDAC (Translational Development Acquisition Corp.) as Chairman and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.